Want to see PSTV full AI Analyst Report?
PSTV Stock Chart & Stats
$0.58
-$0.05(-4.03%)
At close: 4:00 PM EST
$0.58
-$0.05(-4.03%)
Day’s Range― - ―
52-Week Range$2.90 - $23.44
Previous CloseN/A
Volume69.06K
Average Volume (3M)199.45K
Market Cap
$25.74M
Enterprise Value$12.63
Total Cash (Recent Filing)$3.02M
Total Debt (Recent Filing)$725.00K
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Aug 19, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-417.08
Shares Outstanding6,883,106
10 Day Avg. Volume164,730
30 Day Avg. Volume199,446
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.98
Price to Sales (P/S)7.65
P/FCF Ratio-1.91
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$39.67Price Target Upside6739.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.92
Revenue Forecast (FY)$6.04M
Bulls Say, Bears Say
Bulls Say
Regulatory Support (Orphan Drug)Orphan Drug designation for the lead rhenium radiotherapeutic provides development incentives, potential market exclusivity and greater partner interest. These structural benefits can lower long-term development costs and improve commercialization prospects in rare CNS indications.
Low Leverage / Modest DebtVery low reported leverage reduces near-term solvency pressure and interest obligations, giving management financial flexibility. For a clinical-stage developer this structural balance-sheet strength supports continued R&D and optionality while pursuing partnerships or equity raises.
High Gross MarginsExceptionally high gross margins imply attractive unit economics for future product or diagnostic sales. If the company scales commercial diagnostics or therapies, these sustainable margin levels support long-term profitability potential once revenue growth is achieved.
Bears Say
Sustained Cash BurnDeep and persistent negative operating and free cash flow require ongoing external financing and heighten execution risk. Over months this cash burn constrains R&D and commercialization timing and makes milestone delivery contingent on successful capital access.
Small, Declining Revenue BaseA tiny and shrinking revenue base means current operations cannot support fixed costs, so profitability depends on new product/diagnostic adoption or deals. This structural revenue weakness prolongs reliance on external funding and raises execution risk for commercialization.
Dependence On Equity FinancingUse of an at‑the‑market program and shelf capacity signals recurring reliance on equity markets for liquidity. This structural funding model creates dilution risk and ties strategic timing to market conditions, complicating capital planning for multi‑year clinical development.
Plus Therapeutics News
PSTV FAQ
What was Plus Therapeutics’s price range in the past 12 months?
Plus Therapeutics lowest stock price was $2.90 and its highest was $23.44 in the past 12 months.
What is Plus Therapeutics’s market cap?
Plus Therapeutics’s market cap is $25.74M.
When is Plus Therapeutics’s upcoming earnings report date?
Plus Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 29 days.
How were Plus Therapeutics’s earnings last quarter?
Plus Therapeutics released its earnings results on Apr 16, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.848 by -$0.202.
Is Plus Therapeutics overvalued?
According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued.
Does Plus Therapeutics pay dividends?
Plus Therapeutics does not currently pay dividends.
What is Plus Therapeutics’s EPS estimate?
Plus Therapeutics’s EPS estimate is -0.88.
How many shares outstanding does Plus Therapeutics have?
Plus Therapeutics has 6,883,106 shares outstanding.
What happened to Plus Therapeutics’s price movement after its last earnings report?
Plus Therapeutics reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.848. Following the earnings report the stock price went up 5.31%.
Which hedge fund is a major shareholder of Plus Therapeutics?
Currently, no hedge funds are holding shares in PSTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Plus Therapeutics
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
PSTV Stock 12 Month Forecast
Average Price Target
$39.67
▲(6739.08% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
Senti Biosciences
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
2.91% Insiders
<0.01% Other Institutional Investors
92.32% Public Companies and
Individual Investors